Inositol helps cells respond properly to signals from hormones and neurotransmitters
I find it interesting how few continue beyond 1+ year, and wonder what sort of yo-yo experience that could mean in the future years of benefit programs
Clinically, they may: improve adherence lower system cost reduce injection fatigue expand treatment reach But pills wont replace the fundamentals either
The absence of a contraindication does not mean combination therapy is routinely recommended or well-studied
adults currently use GLP-1 for weight loss Obesity rate: Declined from 39.9 percent (2022) to 36.4 percent (2026) based on self-reported BMI Diabetes diagnosis rate: Stable since 2023 after 15 years of gradual rise Important limitation: Self-reported data
In sum, current evidence positions GLP-1 RAs as a potential cardioprotective strategy in HF, with HF with preserved ejection fraction emerging as the clinically most relevant phenotype for the drug class, especially when occurring in people with obesity with and without diabetes
